Explore

Euro Biosimilars 2019

12th European Biosimilars Congress 2019

Berlin, Germany
15 - 16 April 2019
The conference ended on 16 April 2019

Important Dates

Abstract Acceptance Notification
21st August 2018
Early Bird Deadline
28th December 2018
Final Abstract / Full Paper Deadline
1st January 2019
Abstract Submission Deadline
1st April 2019

About Euro Biosimilars 2019

Dear Sir/Madam, After successful Conference Euro Biosimilars 2018, it is our immense pleasure and honor to request you to participate as a speaker / delegate / exhibitor at 12th European Biosimilars Congress during April 15- 16, 2019 at Berlin, Germany. For more info follow the link: https://biosimilars-biologics.pharmaceuticalconferences.com/europe/ Kindly let us know about your participation interest Regards John Hill | Program Director eurobiosimilars@pharmaceuticalconferences.org

Topics

Cell biology, Molecular biochemistry, Clinical pharmacology and bio pharmaceutics, Molecular bio sciences molecular medicine

Call for Papers

12###sup/sup### European Biosimilars Congress 2019 Organizing Committee invites you to attend the largest assemblage of biologics and biosimilars researchers from around the globe during April 15-16, 2019 at Berlin, Germany.

European Biosimilars Congress is a global annual event. This Biosimilars Congress 2019 brings together scientists, researchers, business development managers, CEOs, directors, IP Attorneys, Regulatory Officials and CROs from around the world. The passage of Biosimilars through a decade at Asia finds much requirement for discussion also focusing the Current Challenges in Developing Biosimilars.

CONFERENCE HIGHLIGHTS

  • Current Challenges in Developing Biosimilars
  • Chemical and Analytical Strategies for Biosimilars
  • Intellectual Property Rights
  • Biological Medicine
  • Emerging Biosimilars in Therapeutics
  • Innovative Clinical Approach in Biosimilars
  • Regulatory Updates on Biosimilars
  • Biosimilars Development in Markets
  • Biosimilars Approval to Biogenerics in Clinical Practice
  • Biopharmaceutical Informatics
  • Consequences of Brexit on Biosimilars
  • BCS and IVIVC Based Biowaivers
  • Biosimilars Market and Cost Analysis
  • Challenges in Biosimilars Pharmacovigilance
  • Legal Issues and BPCI Act
  • Formulation Strategies for Follow-on Biologics
  • Current Agency Expectations for Approval for Biosimilars
  • Biosimilars Research Pipeline
  • Globalization of Biosimilars
  • Drug Delivery and Development
  • Monoclonal Antibody Biosimilars
  • USFDA Approved Biosimilars 

Happily invite attendees from Chief Executives, Directors, Vice Presidents, Department Heads, Leaders and Managers specialising in:

Biologics/Biotechnology/ Biogenerics, Legal Affairs, Pricing and Reimbursement, Regulatory Compliance, Preclinical and Clinical Development, Quality Affairs/ Quality Control, Biopharmaceuticals, Intellectual property, Clinical Immunology, R&D, New Product Development and Pharmacovigilance

From Industries Including:

Clinical Immunology, Immunology, Drug Safety, Preclinical Development, Therapeutic Areas, Business Development, Vaccines Development, Scientific Affairs, Validation, Analytical Characterization, Antibody Discovery, Oncology, Infection and Immunity, Risk Management, Clinical Program, Personalized Medicine, Portfolio Planning, Regulatory Affairs, Pharmacovigilance, Global Strategy and Antibody Engineering

Website Link: https://biosimilars-biologics.pharmaceuticalconferences.com/europe/

###b###a href="https://biosimilars-biologics.pharmaceuticalconferences.com/europe/abstract-submission.php" class="redactor-linkify-object">https://biosimilars-biologics....

Registration link: https://biosimilars-biologics.pharmaceuticalconferences.com/europe/registration.php 

Contact Details:

John Hill

Program Manager | Euro Biosimilars 2019

47 Churchfield Road, London, W3 6AY

Toll Free: +448000148923

eurobiosimilars@pharmaceuticalconferences.org

Keep Up to Date with PaperCrowd

Sign up and follow your favorite conferences.

We are no longer accepting conference submissions on PaperCrowd. We apologise for any inconvenience.